Complement Regulatory Genetic Mutations in the Setting of Autoimmune Thrombotic Thrombocytopenic Purpura: A Case Series

OBJECTIVE: To explore the benefits of adding eculizumab for the treatment of refractory autoimmune thrombotic thrombocytopenic purpura (iTTP) with complement dysregulation. PATIENTS AND METHODS: From January 1, 2014, through July 1, 2017, we identified patients with iTTP defined by ADAMTS13 (disinte...

Descripción completa

Detalles Bibliográficos
Autores principales: Atrash, Shebli, Sasapu, Appalanaidu, Pandey, Soumya, Cottler-Fox, Michele, Motwani, Pooja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124327/
https://www.ncbi.nlm.nih.gov/pubmed/30225434
http://dx.doi.org/10.1016/j.mayocpiqo.2017.11.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124327/
https://www.ncbi.nlm.nih.gov/pubmed/30225434
http://dx.doi.org/10.1016/j.mayocpiqo.2017.11.004

Ejemplares similares